Chemours (NYSE:CC) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Chemours (NYSE:CC) released its quarterly earnings results on Tuesday. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.08), Zacks reports. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. During the same quarter last year, the business earned ($2.54) EPS. The business’s revenue for the quarter was down 1.5% on a year-over-year basis.

Chemours Stock Up 4.9%

CC traded up $0.83 during trading on Tuesday, hitting $17.94. The company had a trading volume of 2,850,245 shares, compared to its average volume of 2,202,822. Chemours has a 1-year low of $10.44 and a 1-year high of $28.67. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.82 and a quick ratio of 0.87. The company has a market cap of $2.70 billion, a PE ratio of -6.80 and a beta of 1.43. The business has a 50-day moving average of $19.67 and a 200-day moving average of $20.06.

Key Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours generated $158 million in operating cash flow and $114 million in free cash flow during the second quarter. Titanium Technologies sales also increased 1% year over year, while the company cited growth opportunities tied to data-center demand. Chemours reports second-quarter sales and loss
• Positive Sentiment: Management maintained its 2026 outlook for 1% to 5% sales growth and adjusted EBITDA of $775 million to $825 million. Full-year revenue guidance of $5.9 billion to $6.1 billion is broadly in line with consensus. Chemours reports second-quarter results
• Neutral Sentiment: The board declared a quarterly dividend of $0.0875 per share, providing continued shareholder income but offering limited evidence of improving operating performance. Chemours announces third-quarter dividend
• Negative Sentiment: Second-quarter adjusted EPS was $0.42, below the $0.43 Zacks consensus and other analyst estimates near $0.50; earnings also declined from $0.58 a year earlier. Revenue fell 1% to $1.591 billion, and adjusted EBITDA decreased to $247 million from $260 million. Chemours misses second-quarter earnings and revenue estimates
• Negative Sentiment: Chemours reported a $274 million GAAP net loss, or $1.81 per share, with litigation costs weighing on results and overshadowing otherwise favorable data-center growth. Third-quarter revenue guidance of $1.5 billion to $1.6 billion is below the $1.6 billion consensus, reinforcing near-term execution concerns. Chemours litigation costs overshadow data-center growth

Wall Street Analysts Forecast Growth

CC has been the subject of a number of analyst reports. Morgan Stanley upped their price objective on shares of Chemours from $17.00 to $21.00 and gave the company an “equal weight” rating in a research report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Chemours in a research report on Friday, July 17th. Mizuho cut their price target on Chemours from $30.00 to $25.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 1st. Alembic Global Advisors reissued an “overweight” rating and issued a $30.00 price target on shares of Chemours in a report on Wednesday, May 13th. Finally, Truist Financial raised their price objective on Chemours from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Chemours presently has an average rating of “Moderate Buy” and a consensus price target of $24.10.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Abel Hall LLC bought a new position in Chemours during the 4th quarter worth approximately $128,000. Captrust Financial Advisors acquired a new position in shares of Chemours in the 4th quarter worth approximately $139,000. Brooklyn Investment Group bought a new stake in shares of Chemours in the 4th quarter valued at approximately $145,000. Franklin Resources Inc. bought a new stake in shares of Chemours in the 4th quarter valued at approximately $144,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in shares of Chemours during the 2nd quarter valued at approximately $116,000. 76.26% of the stock is owned by institutional investors and hedge funds.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.